Enteral Lorazepam as a weaning startegy in Refractory status epilepticus

Enteral lorazepam as a weaning strategy for midazolam responsive refractory status epilepticus : an open label Randomized Control Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056641

Enrollment

Registered

2023-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: G02- Meningitis in other infectious andparasitic diseases classified elsewhere

Interventions

Intervention1: enteral lorazepam: In all patients whose seizures will be responding to midazolam, the weaning of midazolam will be attempted for the first time 24 hours after the clinical and electrog

Eligibility

Inclusion criteria

Inclusion criteria: 1month to 14 year children with frequent seizures evolving into refractory status epilepticus

Exclusion criteria

Exclusion criteria: Conditions like GI bleeding where enteral lorazepam cannot be given 2. Refractory status epilepticus who have failed coma induction with midazolam, requiring iv anesthetics other than midazolam

Design outcomes

Primary

Measure	Time frame
Duration in days to taper midazolam after starting enteral lorazepam compared to conventional weaning by midazolam aloneTimepoint: 24hrs,36hrs,48hrs,72 hrs	—

Secondary

Measure	Time frame
No. days with refractory status epilepticus before starting enteral lorazepam 2.Dose of midazolam infusion when lorazepam was started (mg/kg/ minute) 3.Dose of enteral lorazepam at initiation (mg/kg/d) Timepoint: 2years	—

Countries

India

Contacts

Public ContactManas Ranjan Sahoo

AIIMS Raipur

drmrsahoo@gmail.com07893230151

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026